ACADIA Pharmaceuticals stock. Business context for investors.

ACADIA Pharmaceuticals is a U.S.-listed biopharma company focused on neuroscience treatments and commercial-stage execution.

ACADIA Pharmaceuticals Inc. (ISIN US0042251084) develops and commercializes therapies for central nervous system disorders, with a U.S. listing on Nasdaq under the ticker ACAD. The company’s business is anchored by neuroscience medicines and a U.S. market presence that gives investors a clear operating frame.

Business model

ACADIA’s profile centers on prescription medicines, regulatory execution, and commercialization in specialty care. That mix makes revenue quality, launch cadence, and payer access more important than broad market swings for the underlying story.

Investor focus

For ACADIA, the key questions are product adoption, label breadth, and the pace of new prescriptions. In biopharma, those operating details often matter more than the headline sector mood.

Lead products

NUPLAZID remains the company’s best-known commercial product, and it is the clearest example of how ACADIA monetizes its neuroscience focus. The product mix matters because specialty-pharma concentration can amplify both execution gains and setbacks.

Trading snapshot

Nasdaq-listed ACADIA Pharmaceuticals trades in U.S. dollars. The latest quote, market cap, and next earnings date should be read directly from the live market data displayed alongside this article.

ACADIA Pharmaceuticals facts

• Company: ACADIA Pharmaceuticals Inc.
• ISIN: US0042251084
• Ticker: ACAD
• Exchange: Nasdaq
• Sector / Industry: Health Care / Biotechnology